This increase has been attributed to population growth and lower asthma-related mortality.
GlobalData data shows that 12-month confirmed cases of severe asthma in eight major markets (8MM) are expected to grow at an annual growth rate (AGR) of 0.49%, from 1.81 million cases in 2023 to 1.89 million cases in 2033 example.
The lifetime prevalence of diagnosed cases is also expected to increase, with an average annual growth rate of 0.30%, reaching 3.39 million cases by 2033.
During the forecast period, the United States is expected to have the highest number of confirmed cases of severe asthma in 12 months over 8MM, with approximately 852,000 cases, while Japan is expected to have the lowest number, with approximately 24,000 cases.
Molly Moran, senior epidemiologist at GlobalData, said the increase was attributed to population growth and lower asthma-related mortality.
“Because severe asthma is often a lifelong condition, population growth will lead to an increase in the burden of severe asthma,” Moran said.
*8MM = United States, France, Germany, Italy, Spain, United Kingdom, Japan and Canada.
